Universal Health Services (BSP:U1HS34) Research & Development: R$0 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BSP:U1HS34 Universal Health Services Inc BSP:U1HS34
85 GF Score
Price R$216.30
GF Value R$301.81
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Universal Health Services Research & Development?

Universal Health Services BSP:U1HS34 85 Research & Development is R$0 Mil as of Jun. 2026. GuruFocus rates BSP:U1HS34 with a GF Score™ of 85/100 and a GF Value™ of R$301.81 (Modestly Undervalued). The stock has 2 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Universal Health Services's Research & Development for the three months ended in Jun. 2026 was R$0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Jun. 2026 was R$0 Mil.

Universal Health Services  (BSP:U1HS34) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Universal Health Services Research & Development Related Terms

Universal Health Services Research & Development Historical Data

* Premium members only.

The historical data trend for Universal Health Services's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Universal Health Services Research & Development Chart

Universal Health Services Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Universal Health Services Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
BSP:U1HS34
85GF Score
Universal Health Services Inc BSP:U1HS34
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Universal Health Services Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was R$0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of R$0 Mil mean?
Universal Health Services (BSP:U1HS34) has a Research & Development of R$0 Mil as of Jun. 2026. Research and development expense is the total cost for research and development activities. View historical data on Universal Health Services and its competitors.
Is Universal Health Services' Research & Development too high?
Universal Health Services' current Research & Development is R$0 Mil. Overall, Universal Health Services has a GF Score™ of 85/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Universal Health Services' Research & Development compare to ENSG and EHC?
Universal Health Services' Research & Development of R$0 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Healthcare Providers & Services company?
A good Research & Development depends on the Healthcare Providers & Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Universal Health Services and its competitors. Universal Health Services's current Research & Development is R$0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Universal Health Services stock overvalued right now?
Based on GuruFocus' analysis, Universal Health Services (BSP:U1HS34) is currently considered Modestly Undervalued. The stock's GF Value™ is R$301.81, compared to a current price of R$216.30 — trading 28.3% below its estimated fair value. The current Research & Development is R$0 Mil. Universal Health Services' overall GF Score™ is 85/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Universal Health Services (BSP:U1HS34), the current Research & Development is R$0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Universal Health Services (BSP:U1HS34) Overvalued in 2026?

Based on GuruFocus' analysis, Universal Health Services stock appears to be undervalued. The current stock price of R$216.30 is trading 28.3% below its estimated GF Value™ of R$301.81. GuruFocus considers Universal Health Services to be Modestly Undervalued.

Key valuation signals for BSP:U1HS34:

  • Research & Development: R$0 Mil
  • GF Value™: R$301.81 vs. price of R$216.30 (28.3% below fair value)
  • GF Score™: 85/100 with 2 warning signs

No single metric tells the full story. See the BSP:U1HS34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Universal Health Services Business Description

Address 367 South Gulph Road, Universal Corporate Center, P.O. Box 61558, King Of Prussia, PA, USA, 19406-0958
Universal Health Services Inc offers healthcare services through its behavioral health centers, acute care hospitals, and related outpatient facilities. As of late 2025, the company operated 346 inpatient behavioral health centers, 29 acute care hospitals, and many supportive outpatient facilities. Its operations are concentrated in the U.S, particularly in Nevada (21% of 2025 operating profits), Texas (19%), and California (13%), although it does have some exposure to the UK behavioral health market (6% of 2025 sales) too. While its acute care services account for over 55% of revenue, the behavioral health centers sport higher margins and account for over 55% of pretax profits.
85GF Score

Get the complete analysis for BSP:U1HS34

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$216.30
Price
R$301.81
GF Value